about
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsChallenges in multiple myeloma diagnosis and treatment.Stem cell transplantation for multiple myeloma: current and future statusPrognostic factors in CLLChronic lymphocytic leukemia: treatment of relapse.Second-generation TKIs: which and when?Prognostic markers in AML: focus on CBFLDeconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis.Dissecting reprogramming, differentiation and conversion with network biology.Myeloid differentiation and the leukemia-initiating cellReconsidering marrow stem cell cycle status: insights into an actively cycling hematopoietic stem cell population.Altered microenvironmental regulation of CML stem cells.The polycythemia vera stem cell.Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Conclusion: advances in current treatment for patients with newly diagnosed multiple myelomaFungal infections: diagnostic problems and choice of therapy.Advances in current treatment for patients with newly diagnosed multiple myeloma.Biology of CML stem cells: the basis for clinical heterogeneity?Optimal induction and post-remission therapy for acute myeloid leukemia.Treating older patients with AML.Novel strategies in treatment of acute promyelocytic leukemia.Antibiotic therapy in hematological neutropenic patients: what is the news?Viral infections in patients with hematological malignancies.The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.Molecular basis of myelodysplastic syndromesInitial treatment for patients with chronic myeloid leukemia.Stem cell persistence in chronic myeloid leukemia.Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors.Where are we going with CML research?Normal and leukemic stem cells.Change in prognostic factorsModern therapy of young and adult Ph-ALL.Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Advances in unrelated cord blood transplants in malignancies.Adoptive immunotherapy for myeloid malignancies.New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.Targeting leukemia stem cells with HDAC inhibitors and modulators of the DNA damage response.
P1433
Q26863610-7240D6C4-6756-4EF0-B61C-6DFB4D5DE357Q36852225-0C04438B-CC51-4A61-8F15-C189A05D9659Q36852229-19AF7937-365B-41AB-8A72-A5F3F8C94107Q36852233-FFA8DAB5-1C11-4539-BE33-50C6EB0CC76EQ36852238-30E4310D-F4BC-430C-ACAA-3DABEAC3F6CBQ36852243-7A23F3DD-4FEB-4C72-B5F9-1FE953DEC082Q36852251-A16BA793-1253-4204-8989-BDA11493226AQ36852447-B711F8F8-8885-44E8-961D-99AE8D34A3FEQ36852451-FB43BBF8-7D61-4FA3-A131-96AF6F0B651EQ36852455-B70E2E54-E9F2-4843-991F-944284A7979BQ36852459-E6904B75-1A65-4392-82E7-53BD4026E863Q36852464-4CDC6756-4D5A-4D06-B822-F8837B33C01AQ36852469-785A13AC-67FD-42F1-B2F5-D261C7F59225Q38833534-A79A909D-677C-42C0-A19D-D44030509B0CQ38833538-BB823C6F-4029-4EAB-9E5A-134D39E93572Q38833540-83B7CD92-18B9-440E-A34F-9516ED7B2B10Q39202789-36C89B3C-03F6-46A9-8F36-29F89E572AC5Q39769576-9076F098-4838-45B8-B4F3-E225EA23A947Q39769583-4E965EE6-4079-4E89-8E9D-41814C89AB97Q40817111-95291883-5248-41A1-A7C2-FE7E22A7ECFEQ40817146-737B03C8-DDA1-4195-9D98-0FC1829BA40BQ40817185-DFA00572-7C11-41F2-8D9C-AA480C5A9F87Q40817221-89EFA0DE-AD35-4C2A-B58E-7056E2A98783Q40817293-DB3BE014-A118-4F5B-AD91-16F304A5B2BAQ40817325-3E0CBBD8-6D79-4B56-8EA6-9359CF772D4AQ40817438-075368AD-7C8F-4C40-9DF6-50F9EDFF4D9DQ40817471-086A14C4-EFFB-4467-9E1E-05D6ACA768DAQ40817501-4764DD58-84BA-40D9-A899-3D2BD343C803Q40817591-03E068F0-B143-475D-AD05-C0AF54A727D1Q40817619-B0A75EB1-F241-4E14-8629-B19AE08EC6A2Q40817656-13B1AFA3-8084-49AA-BFFB-78AD8A0D9EB6Q40817695-CCBF25AC-8C47-45CA-8B43-D0C96BD02DDDQ40817732-8F796C56-664C-4D18-9D72-E2702742B858Q40817792-8CA2CF69-D6C5-414C-A2E8-C12E2B77B482Q40817830-36565FB1-1DF8-4ECB-B0D1-197F5EE65B40Q40817866-CA48513B-F5B1-4E80-963E-07687E7199A8Q40819697-E164634F-EDCC-4771-BB84-97BA72BC7A6DQ40819781-891D6230-1DB1-42C2-8518-BE98FC6453A1Q40819847-061E9EE1-EF55-41A4-A09E-A19D670282B6Q40819882-A9E49BCD-7142-424B-9193-D636001106DA
P1433
description
czasopismo naukowe
@pl
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Leukemia supplements
@ast
Leukemia supplements
@en
Leukemia supplements
@es
Leukemia supplements
@it
Leukemia supplements
@nl
type
label
Leukemia supplements
@ast
Leukemia supplements
@en
Leukemia supplements
@es
Leukemia supplements
@it
Leukemia supplements
@nl
prefLabel
Leukemia supplements
@ast
Leukemia supplements
@en
Leukemia supplements
@es
Leukemia supplements
@it
Leukemia supplements
@nl